Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Nutcracker Therapeutics has raised $167.0M in total funding. The most recent round was Series C. The last funding was announced in March 2022.
Nutcracker Therapeutics's investors include ARCH Venture Partners, Bluebird Ventures.
Nutcracker Therapeutics is headquartered in Emeryville, United States.
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Nutcracker Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nutcracker Therapeutics — Funding & Investors." VCBacked, March 14, 2022, https://www.vcbacked.co/company/nutcracker-therapeutics. Accessed August 14, 2026.
VCBacked. (2022). Nutcracker Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/nutcracker-therapeutics
{{cite web |title=Nutcracker Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nutcracker-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated